Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(NQ:
CMND
)
1.310
-0.010 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc
< Previous
1
2
3
4
Next >
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
August 29, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
August 21, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
August 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
August 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
July 31, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
July 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
July 12, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
June 28, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
June 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
June 11, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
May 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
May 07, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Applies to Cease Being a Reporting Issuer in Canada
April 30, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
April 17, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
April 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine CEO Issues Letter to Shareholders
April 09, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
March 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
March 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
February 23, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
February 05, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.